XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California. XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohn's disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company's developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited.

Aaron Industries makes a lot of products you might be familiar with, but under different names. The pharmaceutical company makes approximately 75 different branded and private-label generic products, including alcohol, hydrogen peroxide, mouthwash, hair gel, and antacids and laxatives. It also produces cold medicine and cough suppressants and personal care products such as body sprays and lotions, as well as food-grade chemicals. Brands include Tussin, Pharmacist Preference, and Peptic Relief. Aaron Industries provides contract manufacturing and logistics services. The company operates two manufacturing facilities, one in California and one in South Carolina.

Salix Pharmaceuticals, Ltd. company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. As of December 31, 2008, the Company’s products were XIFAXAN (rifaximin) Tablets 200 milligram; MOVIPREP; OSMOPREP, VISICOL Tablets, AZASAN Azathioprine Tablets, USP, 75/100 milligram; ANUSOL-HC 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC 25 milligram Suppository (Hydrocortisone Acetate); PROCTOCORT Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 milligram; PEPCID (famotidine) for Oral Suspension; Oral Suspension DIURIL (Chlorothiazide); APRISO (mesalamine) extended-release capsules 0.375 grams, and COLAZAL (balsalazide disodium) Capsules 750 milligram.

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

Minster Pharmaceuticals plc, through its subsidiary, Minster Research Limited, develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions in the United Kingdom. Its products pipeline comprises Tonabersat, which is in Phase IIb clinical trial for the prevention and treatment of migraine; and Sabcomeline, a Phase IIa clinical trial product for the management of cognitive decline and negative symptoms in schizophrenia. The company is based in Saffron Walden, the United Kingdom.

Beijing Tongrentang Co., Ltd. company makes and sells a variety of traditional Chinese herbal medicines under the Tongrentang brand. Products include treatments for a number of maladies including colds and fevers, and preparations designed to improve circulation and kidney function. Tongrentang also exports its herbal remedies and has expanded beyond Chinese borders through a number of joint ventures and subsidiaries, establishing retail drug stores and clinics specializing in traditional Chinese medicine. The company's origins date back more than 300 years as a family business offering its remedies in Beijing during the Qing Dynasty.

Roxane Laboratories, a US-based subsidiary of Germany's Boehringer Ingelheim, oversees the development, manufacturing, and marketing of its parent company's multisource (generic) drugmaking business in the US. It sells about 75 medications in 250 package sizes, focusing on oral liquids, sustained-release and controlled-release tablets, cancer drugs, and nasal sprays. It also distributes narcotics, such as meperidine (generic Demerol) and methadone. Products developed and marketed by Roxane are manufactured by its sister company, Boehringer Inghelheim Roxane, also located in Columbus, Ohio.

Neos Therapeutics makes generic drugs take their time. The contract pharmaceutical manufacturer develops and manufactures branded and generic prescription and OTC pharmaceuticals with an emphasis on time-released formulations. Its products include cold and cough remedies and nutritional supplements. Customers are primarily pharmaceutical distributors and other manufacturers. Neos Therapeutics was slapped hard by the FDA in 2007 for manufacturing unapproved drugs. The action prompted a change in ownership and the company was required to re-file its drug applications in order to resume manufacturing.

PharmaNet, a global, drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. PharmaNet offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. In addition, PharmaNet offers technology tools for managing clinical trial data.

Celsis International plc company was founded in 1992. Celsis International is all about playing it safe. Through the company's Product Group, it makes rapid diagnostic and monitoring systems used to detect and measure microbial contamination in consumer products and food. Its RapidScreen assays are used by makers of personal care goods, cosmetics, OTC drugs, and a variety of beverages. CellScan Innovate is used by dairy producers. The division, which accounts for little more than half of Celsis International's sales, counts among its customers Dow Corning and Gillette. Celsis Laboratory Group performs quality testing for the cosmetics, drug, and chemicals industries.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.